In a trial where 92 treatment-naïve patients with advanced head and neck squamous cell carcinoma received standard therapy either with or without nimotuzumab, EGFR expression showed a significant correlation with patient survival in patients treated with nimotuzumab and chemoradiation [25]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.